TREM-1

TREM-1

TREM-1 분자 정보

Molecule Name
Triggering receptor expressed on myeloid cells 1
분자 별명
TREM1,CD354
Drug Development Progress
임상 약물 수6
시판 약물 수0
최고 연구 개발 단계Phase 2 Clinical
표적 별명
Triggering Receptor Expressed On Myeloid Cells 1,CD354 Antigen,Triggering Receptor Expressed on Myeloid Cells-1,TREM-1,TREM1,CD354,Triggering receptor expressed on monocytes 1
분자 배경
Triggering receptor expressed on myeloid cells 1 (TREM1) is also known as CD antigen CD354, and is a type I transmembrane protein with a single Ig-like domain. TREM1 is highly expressed in adult liver, lung and spleen than in corresponding fetal tissue. TREM-1 / CD354 stimulates neutrophil and monocyte-mediated inflammatory responses, and also triggers release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers. Amplifier of inflammatory responses that are triggered by bacterial and fungal infections and is a crucial mediator of septic shock. TREM1 can interacts with TYROBP / DAP12.

TREM-1 제품 목록

Species
  • Human(1)
Tag
  • Fc Tag(1)
Host
  • HEK293(1)
Conjugate
  • Unconjugated(1)
Grade
  • RUO(1)
Low Endotoxin
  • Yes(1)
분자Cat. No.Product Name종Host구조순도Activity규격 및 가격
TREM-1
Human TREM-1 / CD354 Protein, Fc Tag, low endotoxin
Human
HEK293
SDS-PAGE
ELISABLI

$395.00

100ug
You Have Viewed 1-1 Of 1 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
NangibotideLR-12Phase 2 ClinicalInotrem
Coronavirus Disease 2019 (COVID-19); Shock, Septic
상세
ABBV-8736ABBV-8736Phase 2 ClinicalAbbvie Inc
Crohn Disease; Inflammatory Bowel Diseases
상세
TREM-1 antibody (Boehringer Ingelheim)Phase 1 ClinicalBoehringer Ingelheim International Gmbh
Autoimmune Diseases
상세
CEL383CEL-383Phase 1 ClinicalCelsius Therapeutics Inc
Inflammatory Bowel Diseases
상세
TREM 1 antibody(Boehringer Ingelheim International Gmbh)TREM 1 antibody(Boehringer Ingelheim International Gmbh)Phase 1 ClinicalBoehringer Ingelheim International Gmbh
Immune System Diseases
상세
PY-159PY-159Phase 1 ClinicalCentre for the Commercialization of Antibodies and Biologics
Neoplasms; Solid tumours
상세
Customer Reviews